Chimerix, Inc. (NASDAQ:CMRX) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET

Company Participants

Michelle Laspaluto - Vice President of Strategic Planning and Investor Relations

Mike Andriole - President and CEO

Josh Allen - Chief Technology Officer

Allen Melemed - Chief Medical Officer

Conference Call Participants

Kevin Strang - Jefferies

Naureen Quibria - Capital One

Joel Beatty - Baird

Ed White - H.C. Wainwright

Soumit Troy - Jones Trading

Joseph Thome - TD Cowen

Operator

Good morning, ladies and gentlemen, and welcome to the Chimerix Second Quarter 2023 Earnings Conference Call.

I would now like to introduce you to your host for today's call, Michelle Laspaluto, Vice President of Strategic Planning and Investor Relations at Chimerix. Please proceed.

Michelle Laspaluto

Thank you. Good morning, everyone, and welcome to the Chimerix Second Quarter 2023 Financial and Operating Results Conference Call. This morning, we issued a press release related to our second quarter operating update. You can access the press release in our Investors section of the website.

With me on today's call are President and Chief Executive Officer, Mike Andriole; Chief Medical Officer, Allen Melemed; and Chief Technology Officer, Josh Allen. Before we begin, I'd like to remind you that the statements made on today's call include forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors. These risks and uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Please refer to our filings with the SEC for a more complete disclosure of these risks and uncertainties.

At this time, I would now like to turn the call over to our President and Chief Executive Officer, Mike Andriole.

Mike Andriole

Thanks, Michelle, and good morning, everyone, and thank you for joining us. I'm delighted to be hosting the call for the first time as CEO and to provide an update on our second quarter results, which were characterized by focused execution across both the ONC201 and ONC206 clinical programs.

Starting first with ONC201 in the ACTION study. We've experienced strong engagement and enthusiasm across the neuro-oncology community globally for this study, driven in part by the scale of the unmet need in H3 K27M glioma, where there are very few treatment options for these patients beyond radiation therapy. Additionally, high-grade glioma is a subset within the broader field of oncology, particularly in pediatrics that sees relatively few randomized controlled Phase 3 studies. This reality further adds to the engagement we are seeing from investigators and sites, which have a few competing studies in the field.